Skip to content

CorMedix CRMD Other intangible assets—net

Other intangible assets—net at other companies

ITG
Integer HoldingsITGR
$806.34M-5.8%
IAR
Integra LifeSciencesIART
$1.11B-6.9%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$470.4M-3.1%
Pfizer logo
PfizerPFE
Merck & Co. logo
Merck & Co.MRK
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's other intangible assets—net?
CorMedix (CRMD) reported other intangible assets—net of $368.77M in Q1 2026.
How has CorMedix's other intangible assets—net changed year-over-year?
CorMedix's other intangible assets—net increased by 20476.4% year-over-year, from $1.79M to $368.77M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.